Introduction

The survival rate of immunocompromised patients, such as those with hematological malignancies, solid organ transplant, acquired immunodeficiency syndrome, and those receiving corticosteroid or cytotoxic therapy for a non-malignant disease, has progressively improved due to the remarkable advances in diagnostic and therapeutic options (1). Simultaneously, there has been an increase in the number of immunocompromised patients with life threatening complications requiring intensive care unit (ICU) treatment. ICU admission is necessary in up to 15% of patients with acute leukemia and 20% of bone marrow transplantation recipients, and the main reason for ICU referral in this patient population is acute hypoxemic respiratory failure, which is associated with a high mortality rate, particularly in patients requiring endotracheal intubation. The application of non-invasive ventilation (NIV), and thus the avoidance of endotracheal intubation and invasive mechanical ventilation with its side effects, appears therefore of great importance in this patient population. Early trials supported the benefits of NIV in these settings, and the 2011 Canadian guidelines for the use of NIV in critical care settings suggest the use of NIV in immune-compromised patients with a grade 2B recommendation. However, the very encouraging results from initial seminal trials were not confirmed in subsequent observational and randomized clinical studies, questioning the beneficial effect of NIV in immune-compromised patients. Based on these observations, a French group led by Azoulay decided to assess whether early intermittent respiratory support with NIV had a role in reducing the mortality rate of immune-compromised patients with non-hypercapnic hypoxemic respiratory failure developed in less than 72 h, and hence conducted a multicenter randomized controlled trial (RCT) in experienced ICUs in France. This perspective reviews the findings from their RCT in the context of the current critical care landscape, and in light of recent results from other trials focused on the early management of acute hypoxemic respiratory failure.

Keywords: Non-invasive ventilation (NIV); respiratory failure; immunosuppression

Submitted Jan 11, 2016. Accepted for publication Jan 21, 2016.
doi: 10.21037/jtd.2016.02.11
View this article at: http://dx.doi.org/10.21037/jtd.2016.02.11

Non-invasive ventilation in immunocompromised patients with acute hypoxemic respiratory failure

Lorenzo Del Sorbo¹, Angela Jerath²,³, Martin Dres⁴, Matteo Parotto²,³

¹Interdepartmental Division of Critical Care Medicine, ²Department of Anesthesia, University of Toronto, Toronto, ON, Canada; ³Department of Anesthesia and Pain Management, Toronto General Hospital, Toronto, ON, Canada; ⁴Keenan Research Center at the Li Ka Shing Knowledge Institute of St, Michael's Hospital, Toronto, ON, Canada

Correspondence to: Matteo Parotto, MD, PhD. Department of Anesthesia and Pain Management, Toronto General Hospital, EN 429-200 Elizabeth Street, M5G 2C4 Toronto, ON, Canada. Email: matteo.parotto@uhn.ca.

Abstract: The survival rate of immunocompromised patients has improved over the past decades in light of remarkable progress in diagnostic and therapeutic options. Simultaneously, there has been an increase in the number of immunocompromised patients with life threatening complications requiring intensive care unit (ICU) treatment. ICU admission is necessary in up to 15% of patients with acute leukemia and 20% of bone marrow transplantation recipients, and the main reason for ICU referral in this patient population is acute hypoxemic respiratory failure, which is associated with a high mortality rate, particularly in patients requiring endotracheal intubation. The application of non-invasive ventilation (NIV), and thus the avoidance of endotracheal intubation and invasive mechanical ventilation with its side effects, appears therefore of great importance in this patient population. Early trials supported the benefits of NIV in these settings, and the 2011 Canadian guidelines for the use of NIV in critical care settings suggest the use of NIV in immune-compromised patients with a grade 2B recommendation. However, the very encouraging results from initial seminal trials were not confirmed in subsequent observational and randomized clinical studies, questioning the beneficial effect of NIV in immune-compromised patients. Based on these observations, a French group led by Azoulay decided to assess whether early intermittent respiratory support with NIV had a role in reducing the mortality rate of immune-compromised patients with non-hypercapnic hypoxemic respiratory failure developed in less than 72 h, and hence conducted a multicenter randomized controlled trial (RCT) in experienced ICUs in France. This perspective reviews the findings from their RCT in the context of the current critical care landscape, and in light of recent results from other trials focused on the early management of acute hypoxemic respiratory failure.

Keywords: Non-invasive ventilation (NIV); respiratory failure; immunosuppression

Submitted Jan 11, 2016. Accepted for publication Jan 21, 2016.
doi: 10.21037/jtd.2016.02.11
View this article at: http://dx.doi.org/10.21037/jtd.2016.02.11
non-invasive ventilation (NIV), a technique that provides ventilator assistance without the use of endotracheal tube. NIV carries the advantages of lower ventilator-associated pneumonia and sedation requirements when compared to invasive mechanical ventilation. Furthermore, although side effects of NIV have been described, including facial skin lesions, gastric distension and patient discomfort related to noise, claustrophobia, nasal or oral dryness and nasal congestion, their incidence is low and largely preventable with proper management of the technique (8). Therefore, applying NIV, and thus avoiding endotracheal intubation and invasive mechanical ventilation with its side effects (9,10), may potentially decrease the mortality rate in immunocompromised patients (5,11-13).

This perspective reviews the findings from a recent randomized controlled trial (RCT) assessing whether early intermittent respiratory support with NIV has a role in reducing the mortality rate of immunocompromised patients with non-hypercapnic hypoxic respiratory failure in the context of the current critical care landscape, and in light of recent results from other trials focused on the early management of acute hypoxic respiratory failure.

**Current evidence and recommendations**

Several small single center RCTs have demonstrated positive patient outcomes with the early use of NIV.

Hilbert et al. investigated this hypothesis in a seminal study published in 2001 (12). In this single center RCT, 52 immunocompromised patients (with immunosuppression from several different etiologies) were enrolled if they had pulmonary infiltrates, fever, and hypoxic acute respiratory failure, defined by the presence of dyspnea at rest, respiratory rate greater than 30 breaths/min and an oxygen saturation of less than 90% while breathing on room air, were randomized to receive oxygen (FiO₂ =50%) either by facemask or helmet CPAP at 10 cmH₂O. Overall, significantly fewer patients treated with CPAP required NIV or invasive mechanical ventilation (4 vs. 16 patients; P=0.0002).

Based on these data, NIV is currently considered in many centers as first line treatment for hypoxic respiratory failure in patients with various causes of immunosuppression (15). Moreover, the 2011 Canadian guidelines for the use of NIV in critical care settings suggested the use of NIV in immunocompromised patients with a Grade 2B recommendation (17).

However, these very encouraging results have not been confirmed in subsequent observational (18) and randomized clinical (19) studies. In particular, a recent randomized trial investigated the role of early application of NIV in 86 patients with hypoxic respiratory failure after allogeneic hematopoietic stem cell transplantation (19). In this study, early treatment with NIV did not affect the rate of endotracheal intubation, ICU admission, or patient survival. However, these results may be significantly affected by the high crossover rate given that 16 out of 44 patients in the group allocated to the treatment with conventional oxygen alone received NIV for failure to achieve the oxygenation target.

Therefore, the beneficial effect of NIV in immunocompromised patients has recently been questioned (20). Most of the studies showing a beneficial effect of NIV did not stratify patients for the cause of immunosuppression or timing (early vs. late) of NIV application. Moreover, the expected mortality rate of immunocompromised patients with acute respiratory failure, although still high, has progressively decreased from 50–80% in the year 2001 (12) to current 20–60% (21-23). This is likely due to the advancement in the management...
of critically ill patients, with particular regards to invasive mechanical ventilation, with a consequent potential lower clinical impact provided by treatment with NIV (24).

These observations directed the French group led by Lemiale and Azoulay to a new equipoise on the efficacy of NIV in immunocompromised patients with acute hypoxemic non hypercapnic respiratory failure.

**The new trial: can early non-invasive ventilation (NIV) reduce mortality in immunocompromised patients with acute hypoxemic respiratory failure?**

A multicenter RCT was conducted (25) to assess the potential benefit of early NIV in reducing the mortality rate among immunocompromised patients who developed non-hypercapnic hypoxemic respiratory failure in less than 72 h. In 28 intensive care units from France and Belgium with established experience in delivering NIV, 374 immunocompromised patients with PaO₂ less than 60 mmHg on room air, or respiratory rate greater than 30/min, or signs of respiratory distress, were randomized to receive NIV or conventional oxygen therapy. Of note, patients were stratified according to the cause of immune deficiency in two groups, one with hematologic malignancy or solid cancer, and one with solid organ transplant or long-term/high-dose immunosuppressive treatment. No difference was found between groups with regards to the primary endpoint, the mortality rate at 28 days after randomization (NIV 24.1% vs. oxygen 27.3%; 95% CI, −12.1 to 5.6; P=0.20). Secondary outcomes were also similar between the two groups: proportion of patients requiring endotracheal intubation (NIV 38.2% vs. oxygen 44.8%; 95% CI, −16.6 to 3.4; P=0.20), time to intubation, ICU-acquired infections, duration of mechanical ventilation, and length of stay in ICU and hospital. Also the analysis of the two pre-specified subgroups did not result in any significant difference. The conclusion of the investigators was that among immunocompromised patients admitted to the ICU with hypoxemic acute respiratory failure, early NIV compared with oxygen therapy alone did not reduce 28-day mortality.

Table 1 highlights design and results of this trial in comparison to the previous RCTs from Antonelli et al. and Hilbert et al.

This was a large and well conducted RCT assessing the early use of NIV. There was a high protocol adherence among institutions with expertise in delivering NIV and caring for immunocompromised patients. This trial also powered the primary outcome to reducing patient mortality in comparison to the trials performed by Antonelli and Hilbert et al. who focused on reducing the need for intubation. However, this RCT carries a few limitations, acknowledged by the investigators. In particular, the lower mortality rate than expected in the control group reduced the power of the study to find a significant difference in the primary outcome. Indeed, the trial was designed anticipating a mortality of 35% in the oxygen treated group, whereas the observed mortality rate was 27.3%. As a result, the possibility of drawing definitive conclusions and a clinically meaningful effect based on the study findings is limited.

The reasons of this low mortality rate may be given by a few considerations related to the management of immunocompromised patients. Practices have changed and the prognosis has improved over recent years. Furthermore, the centers involved in the study carry high level of expertise in the field of immunocompromised ICU patients and in NIV. The relationship between case volume and outcomes has been evidenced in this specific field (2). Importantly, the authors speculated that the low mortality rate was potentially due to the higher number of patients in the control group that were treated with heated and humidified high flow oxygen delivered by nasal cannula (HFNC) system compared to the NIV group (44% vs. 31%, P=0.01, respectively). The support provided by HFNC in the control group could have remarkably reduced the need of invasive mechanical ventilation, thus masking the potential efficacious effect of NIV in this patient population. HFNC, which has been gaining clinical and scientific interest (26-47), can deliver up to 100% of heated and humidified fraction of inspired oxygen at a maximum flow rate of 60 L/min. This flow rate is significantly higher than the one delivered via nasal prongs or facemask, which is able to provide a maximum flow of 15 L/min. This limited flow rate is important given that patients with severe respiratory distress often require inspiratory flow rates ranging between 30 and 120 L/min. The consequence of this difference in required inspiratory airflow and provided flow rate is the dilution of the oxygen therapy with room air, so that the delivered FiO₂ is lower than the set FiO₂ (48). The high flow rates delivered by HFNC may partially overcome this issue. In addition, the high airflow delivered directly to the nasopharynx, improves carbon dioxide clearance and reduces dead space, thereby improving alveolar ventilation (29,41,48), and may also induce generation of positive end expiratory pressure (PEEP) (27,30,36,37). In
<table>
<thead>
<tr>
<th>Variables</th>
<th>Antonelli et al. (14)</th>
<th>Hilbert et al. (12)</th>
<th>Squadrone et al. (15)</th>
<th>Wermke et al. (19)</th>
<th>Lemiale et al. (25)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Setting</strong></td>
<td>Single center, 14-bed general ICU</td>
<td>Single center, 16-bed general ICU</td>
<td>Single center, 2 hematology wards</td>
<td>Multicenter, 28 ICUs in France and Belgium</td>
<td></td>
</tr>
<tr>
<td><strong>Study population</strong></td>
<td>Adult</td>
<td>Adult</td>
<td>Adult</td>
<td>Adult</td>
<td></td>
</tr>
<tr>
<td><strong>Criteria for acute hypoxemic respiratory failure</strong></td>
<td>RR &gt;35/min; PaO(_2):FiO(_2) &lt;200 while breathing oxygen; active contraction of accessory muscles of respiration or paradoxical abdominal motion</td>
<td>Pulmonary infiltrates and fever; severe dyspnea at rest; RR &gt;30/min; PaO(_2):FiO(_2) &lt;200 while breathing oxygen</td>
<td>Bilateral pulmonary infiltrates; SpO(_2) &lt; 90% on room air; RR &gt;25/min; respiratory symptom duration &lt;48 h</td>
<td>RR &gt;25/min; PaO(_2):FiO(_2) &lt;300 or SpO(_2) &lt;92% on room air</td>
<td>PaO(_2) &lt;60 mmHg on room air; RR &gt;30/min, or labored breathing or respiratory distress or dyspnea at rest; respiratory symptom duration &lt;72 h</td>
</tr>
<tr>
<td><strong>Criteria for immunosuppression</strong></td>
<td>Solid organ transplant recipients</td>
<td>Neutropenia after chemotherapy or bone marrow transplantation in hematologic cancers; organ-transplant recipients; corticosteroid or cytotoxic therapy for a non-malignant disease; acquired immunodeficiency syndrome</td>
<td>Hematologic malignancy and chemotherapy/bone marrow transplant</td>
<td>Allogeneic hematopoietic stem cell transplant</td>
<td>Hematologic malignancy; solid tumor (active or in remission for less than 5 years); solid organ transplant recipients; long-term (&gt;30 days) or high-dose (&gt;1 mg/kg/d) steroids, or any immunosuppressive drug taken in a high dosage or for more than 30 days</td>
</tr>
<tr>
<td><strong>Number of patients</strong></td>
<td>40 (interventional arm: 20; control arm: 20)</td>
<td>52 (interventional arm: 26; control arm: 26)</td>
<td>40 (interventional arm: 20; control arm: 20)</td>
<td>86 (interventional arm: 42; control arm: 44)</td>
<td>374 (interventional arm: 191; control arm: 183)</td>
</tr>
<tr>
<td><strong>Control arm</strong></td>
<td>Oxygen via Venturi mask</td>
<td>Oxygen via Venturi mask</td>
<td>Oxygen via Venturi mask</td>
<td>Oxygen via nasal insufflation or Venturi mask</td>
<td>Oxygenation modalities and the use of HFNC at clinician’s discretion</td>
</tr>
<tr>
<td><strong>Interventional arm</strong></td>
<td>NIV via facemask; pressure support adjusted to obtain: (I) Vt =8–10 mL/kg; (II) RR &lt;25 b/min; (III) disappearance of accessory muscle activity; (IV) patient comfort</td>
<td>NIV via facemask; pressure support adjusted to obtain: (I) Vt =7–10 mL/kg; (II) RR &lt;25 b/min; (III) PEEP increased by 2 cmH(_2)O, up to 10 cmH(_2)O, until FiO(_2) requirement ≤65%; FiO(_2) for SpO(_2) &gt;90%</td>
<td>CPAP via helmet; CPAP at 10 cmH(_2)O and FiO(_2) 50%</td>
<td>NIV via facemask; pressure support initially set to 15 cmH(_2)O; PEEP initially set to 7 cmH(_2)O; pressure support and PEEP adjusted according to patient tolerance and capillary blood gas analysis</td>
<td>NIV via facemask; pressure support initially set to 15 cmH(_2)O; PEEP 2–10 cmH(_2)O; (II) FiO(_2) and PEEP adjusted to SpO(_2) ≥92%</td>
</tr>
</tbody>
</table>

Table 1 (continued)
### Table 1 (continued)

<table>
<thead>
<tr>
<th>Variables</th>
<th>Antonelli et al. (14)</th>
<th>Hilbert et al. (12)</th>
<th>Squadron et al. (15)</th>
<th>Wermke et al. (19)</th>
<th>Lemiale et al. (25)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Duration of treatment in interventional arm</strong></td>
<td>On day 1, NIV continuously maintained until oxygenation and clinical status improved; subsequently, daily evaluation while breathing supplemental oxygen without ventilatory support for 15 min</td>
<td>NIV for at least 45 min and alternated every 3 h with periods of spontaneous breathing NIV resumed when arterial oxygen saturation &lt;85% or dyspnea worsened</td>
<td>4-day periods consisting of at least 12 consecutive h/day of CPAP; at the end of each period, patients underwent a 6-h screening test during which they breathed through a Venturi mask with FiO$_2$ 30%; if radiological evidence of pulmonary infiltrates, SaO$_2$ &lt;95% or RR &gt;25/min, patients returned to the assigned treatment for another 4-day period</td>
<td>NIV administered intermittently for at least 30 min every 3 h</td>
<td>NIV 60 min session every 4 h, for at least 2 days</td>
</tr>
<tr>
<td><strong>Primary Outcome</strong></td>
<td>Need for endotracheal intubation and mechanical ventilation at any time during the study</td>
<td>Need for endotracheal intubation and mechanical ventilation at any time during the study</td>
<td>Need of mechanical ventilation requiring ICU admission and, among patients admitted to ICU, number of patients who required endotracheal intubation for invasive ventilation</td>
<td>Difference in 100-day mortality</td>
<td>All-cause mortality within 28 days after randomization</td>
</tr>
<tr>
<td><strong>Results</strong></td>
<td>Reduction of number of patients requiring intubation in NIV vs. control group</td>
<td>Reduction of number of patients requiring intubation in NIV vs. control group</td>
<td>Lower number of patients who needed ICU admission for mechanical ventilation and lower intubation rate in CPAP vs. control group</td>
<td>No difference in 100-day mortality</td>
<td>No difference in 28-day mortality</td>
</tr>
<tr>
<td><strong>Notes</strong></td>
<td>Patients with cardiogenic pulmonary edema as the cause of respiratory failure were included in the study</td>
<td>–</td>
<td>–</td>
<td>Of 17 patients failing on control group, 16 crossed over to treatment group, which may have impaired analyses of outcomes</td>
<td>Study power was limited as the mortality in the control group resulted lower than predicted; a higher number of patients in the control group were treated with HFNC</td>
</tr>
</tbody>
</table>

ICU, intensive care unit; RR, respiratory rate; NIV, non-invasive ventilation; Vt, tidal volume; PEEP, positive end expiratory pressure; CPAP, continuous positive airway pressure; HFNC, heated and humidified high flow oxygen delivered by nasal cannula.
healthy volunteers treated with HFNC with closed mouth and a flow rate of 60 L/min the measured PEEP was as high as 7.4 cmH\textsubscript{2}O (30). Furthermore, the heated and humidified airflow delivered with HFNC may provide more comfort to patients requiring oxygen therapy (28,29,48). These potential benefits of HFNC should be studied in a systematic trial and compared to NIV, helmet CPAP and conventional oxygen therapy.

Some other limitations of the study may be related to the actual dose of NIV provided. First, the median durations of treatment were 8 h during the first 24 h, 6 h on day 2 and 5 h on day 3. At present we do not know whether longer durations of NIV would provide different outcomes. Previous studies in immunocompromised patients such as the one from Hilbert et al. (12) reported similar although slightly higher mean durations of treatment, with 9 h of NIV in the first day, and 7 h in the subsequent days. Second, the level of PEEP may play a significant role. As evidenced by the Editorial from Patel and Kress accompanying the study of Lemiale et al. (49), the physiologic goals of NIV in the treatment of acute hypoxic respiratory failure rely on lung recruitment with proper use of PEEP and respiratory muscles unloading with addition of pressure support ventilation. Physiologic studies examining use of NIV in acute lung injury have suggested that a PEEP of at least 10 cmH\textsubscript{2}O is required to significantly improve PaO\textsubscript{2}:FiO\textsubscript{2} ratio with therapy (50). The protocol of Lemiale et al. allowed an initial PEEP between 2 and 10 cmH\textsubscript{2}O, and then adjusted (together with FiO\textsubscript{2}) in order to maintain the peripheral capillary oxygen saturation at 92% or greater. Even if at present it is unclear and difficult to estimate the optimal clinical PEEP setting during NIV, either too low or too high PEEP values could potentially have deleterious consequences. Furthermore, interface-related problems such as facemask leaks or poor patient tolerance may limit accurate titration of PEEP and pressure support ventilation, thus decreasing the efficacy of NIV delivered via facemask (49). Third, excessive NIV support may cause alveolar overdistension or alveolar recruitment and derecruitment, the two main mechanisms of ventilator-induced lung injury (VILI), which may exacerbate the already established injury in patients with acute respiratory failure (48). The possible role of NIV in contributing to VILI may hence provide another explanation for the lack of efficacy of NIV in immunocompromised patients. Interestingly, Carteaux et al. assessed expired tidal volume in patients undergoing NIV for de novo acute hypoxemic respiratory failure in a recent prospective observational study involving 62 patients in a single institution university medical ICU, showing that delivered tidal volumes are higher than expected (49). In particular, the median (interquartile range) tidal volume was 9.8 mL/kg predicted body weight (8.1–11.1 mL/kg), although the targeted tidal volume was 6–8 mL/kg predicted body weight. In this study, high tidal volume was independently associated with NIV failure, which occurred in 51% of the cases. In the sub-group of patients with PaO\textsubscript{2}:FiO\textsubscript{2} of less than 200 mmHg a tidal volume of 9.5 ml/kg accurately predicted NIV failure with a sensitivity of 82% and a specificity of 87%. These data are remarkable with regards of the potential contributing role of high tidal volume during NIV to VILI. In Lemiale et al.’s investigation, the median expiratory tidal volumes were 8.8 mL/kg of ideal body weight on day 1, 9.1 on day 2 and 9.5 on day 3, respectively. Although there were no significant differences in tidal volumes according to NIV success vs. failure or between survivors and non-survivors, the study may have not been adequately powered to make these distinctions based on tidal volume, and the role of excessively high tidal volumes achieved during NIV may have been underestimated.

Also differences in patient populations may be one of the reasons for the different findings in Lemiale et al.’s trial with respect to previous studies. Their patients showed lower degrees of tachypnea compared to Antonelli et al. and Hilbert et al.’s studies (respiratory rate of 25–27/min vs. 35–38/min) suggesting a difference in severity of the acute condition.

**Limitations of current knowledge and future directions**

Where do the recent findings from Lemiale et al.’s study leave the clinician at the bedside caring for immunocompromised patients in the ICU? Several questions remain open:

(I) The role of HFNC alone or in combination with NIV (using HFNC in between NIV sessions) in this patient population will need further investigation. As mentioned above, the higher number of patients in the control group that were treated with HFNC system compared to the NIV group in Lemiale et al.’s study may have partially explained the lower-than-predicted mortality observed. The data from the recent FLORALI study report that in a post hoc adjusted analysis that included the 238 patients with severe initial hypoxemia (PaO\textsubscript{2}:FiO\textsubscript{2} ≤200 mmHg), the intubation rate was significantly lower among patients who received high-flow oxygen than among patients in the other two
A multicenter parallel RCT in four intensive care units assessing the role of HFNC vs. Venturi mask oxygen in immunocompromised patients with acute hypoxic respiratory failure was published by the group of Lemiale and Azoulay. Patients were randomized to 2 h of HFNC or Venturi mask oxygen. The primary endpoint was a need for invasive mechanical ventilation or NIV during the 2-h oxygen therapy period. They found no significant difference between the two groups (15% with HFNC and 8% with the Venturi mask, P=0.36). None of the secondary end-points, which included comfort, dyspnea, and thirst, differed significantly between the two groups. The authors concluded that in immunocompromised patients with acute hypoxic respiratory failure, a 2-h trial with HFNC did not improve mechanical ventilatory assistance or patient comfort compared with oxygen delivered via a simple Venturi mask. However, this study was underpowered given the low event rate and use of a one-sided hypothesis only. Furthermore, this trial focused only upon the initial 2 h after ICU admission and thus the role of HFNC for longer periods of time remains to be assessed.

With improving technology in the near future, NIV might be delivered with interfaces that minimize facemask leaks thus improving the efficacy of treatment and leading to better patient outcomes. Furthermore, our capability to control tidal volumes more accurately may increase, helping us avoid propagation of injury through VILI.

The concern around the potential detrimental effects of delaying intubation in patients who receive NIV remains open. A recent secondary analysis of a prospective observational cohort study published by Kangelaris et al. analyzed data on 457 patients with acute respiratory distress syndrome. Of them 106 (23%) were not intubated at the time of meeting all other acute respiratory distress syndrome criteria. Non-intubated patients had lower morbidity and severity of illness than intubated patients; however, mortality at 60 days was the same (36%) in both groups (P=0.91). Of the 106 non-intubated patients, 36 (34%) required intubation within the subsequent 3 days of follow-up, and this late-intubation subgroup had significantly higher 60-day mortality (56%) when compared with both early intubation group (36%, P<0.03) and patients never requiring intubation (26%; P=0.002). The increased mortality in the late intubation group persisted at 2-year follow-up (52). However, the authors reported that there was no evidence that NIV modified the association between intubation and mortality, i.e., delaying endotracheal intubation through the use of NIV did not account for increased mortality.

**Conclusions**

NIV remains an attractive modality when caring for immunocompromised patient with acute hypoxemic respiratory failure, in light of its potential to avoid the complications of invasive mechanical ventilation. Further adequately powered trials will help us understand which patient subpopulations will benefit the most from each technique (HFNC, NIV or invasive mechanical ventilation), and to identify the most appropriate timing of application of these techniques.

The ongoing efforts towards optimizing the management of acute hypoxemic respiratory failure in immunocompromised patients keep us hopeful that the mortality of these frail patients will continue to decrease in the coming years.

**Acknowledgements**

None.

**Footnote**

Conflicts of Interest: The authors have no conflicts of interest to declare.

**References**

31. Kernick J, Magarey J. What is the evidence for the use of high flow nasal cannula oxygen in adult patients admitted...


35. Murphy M, Scanlon A. A randomised controlled study suggesting equivalence between full face vs. nasal high flow oxygen delivery on health outcomes. Aust Crit Care 2011;24:139-41.


